How much funding has Clasp Therapeutics raised?

Clasp Therapeutics has raised $150.0M in total funding, most recently a Series A round.

Who are Clasp Therapeutics's investors?

Clasp Therapeutics's investors include Catalio Capital Management, Third Rock Ventures, Novo Holdings A/S, Cure Ventures, Blackbird Ventures, Alexandria Venture Investments.

When was Clasp Therapeutics founded?

Clasp Therapeutics was founded in 2020.

Where is Clasp Therapeutics headquartered?

Clasp Therapeutics is headquartered in Rockville.

What industry is Clasp Therapeutics in?

Clasp Therapeutics operates in Biotech, Healthcare.

How many employees does Clasp Therapeutics have?

Clasp Therapeutics has 11-50 employees.

Clasp Therapeutics

Rockville · Founded 2020 · $150.0M raised

Biotech

Healthcare

Headquarters: Rockville
Employees: 11–50
Founded: 2020
Business Model: B2B

Website: clasptx.com
Total Funding: $150.0M
Last Round: $150.0M Series AMar 2024
Rounds: 1

About

Clasp Therapeutics is a biotechnology company with dual headquarters in Rockville, Maryland and Cambridge, Massachusetts, developing next-generation T cell engagers (TCEs) for precision immuno-oncology. Originally formed in 2020 as ManaT Bio around mutation-associated neoantigen research from Johns Hopkins scientists Bert Vogelstein and Drew Pardoll, the company rebranded and launched publicly in March 2024 with $150 million in seed and Series A financing from Catalio Capital Management, Third Rock Ventures, Novo Holdings, Vivo Capital, and Cure Ventures. Clasp's TCEs target tumor-specific mutant antigens presented via specific HLA types, aiming to reduce the off-tumor toxicity seen with earlier-generation T cell engagers.

Summary

Clasp Therapeutics is a Biotech company based in Rockville, founded in 2020. It has raised $150.0M in total across 1 round, most recently a $150.0M Series A round in Mar 2024. Investors include Catalio Capital Management, Third Rock Ventures and Novo Holdings A/S.